Afamelanotide Patent Expiration

Afamelanotide is Used for managing phototoxic reactions in adult patients with Erythropoietic Protoporphyria (EPP) to increase pain-free light exposure. It was first introduced by Clinuvel Inc in its drug Scenesse on Oct 8, 2019.

Afamelanotide Patents

Given below is the list of patents protecting Afamelanotide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Scenesse US10076555 Methods of inducing melanogenesis in a subject Feb 11, 2025 Clivunel Inc
Scenesse US8334265 Method of treatment of photodermatoses Mar 11, 2029 Clivunel Inc

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳